Robert Leonard Garcea
Physician at Pampas Ct, Boulder, CO
License number
Colorado 32422
Issued Date
Feb 12, 1993
Renew Date
May 1, 2015
Expiration Date
Apr 30, 2017
Type
Physician
Address
Address
2505 Pampas Ct, Boulder, CO 80304
Professional information
Therapeutic And Prophylactic Vaccine For The Treatment And Prevention Of Papillomavirus Infection
US Patent:
8039001, Oct 18, 2011
Filed:
Apr 3, 2009
Appl. No.:
12/418481
Inventors:
Robert L. Garcea - Boulder CO, US
Renee Finnen - Kinston, CA
Renee Finnen - Kinston, CA
Assignee:
The Regents of the University of Colorado, a body corporate - Denver CO
International Classification:
A61K 39/12
US Classification:
4242041, 530300, 435 5
Abstract:
Embodiments of the present invention provide compositions including a complexes of papillomavirus capsid polypeptide L2 and polypeptide including an immunotherapeutic epitope, and GST fusions thereof. Other embodiments also provide complexes comprising chimeras of papillomavirus L2 polypeptides non-covalently associated with papillomavirus L1 polypeptides, and GST fusions thereof. These compositions may be used to elicit immune responses in a patient to papillomavirus. Therapeutic and prophylactic vaccines for the prevention and treatment of viral infection, especially papillomavirus infection and cervical cancers and warts associated therewith, made from compositions of this invention, are also disclosed. Nucleic acids and expression vectors coding for compositions are also disclosed.
Therapeutic And Prophylactic Vaccine For The Treatment And Prevention Of Papillomavirus Infection
US Patent:
7763259, Jul 27, 2010
Filed:
Jan 6, 2004
Appl. No.:
10/541895
Inventors:
Robert L. Garcea - Boulder CO, US
Renee Finnen - Denver CO, US
Renee Finnen - Denver CO, US
Assignee:
The Regents of the University of Colorado - Denver CO
International Classification:
A61K 39/12
US Classification:
4242041, 435 6
Abstract:
This invention provides compositions including a chimera of papillomavirus capsid polypeptide L2 and polypeptide including an immunotherapeutic epitope, and GST fusions thereof. The present invention also provides complexes comprising chimeras of papillomavirus L2 polypeptides non-covalently associated with papillomavirus L1 polypeptides, and GST fusions thereof. These compositions may be used to elicit immune responses in a patient to papillomavirus. Therapeutic and prophylactic vaccines for the prevention and treatment of viral infection, especially papillomavirus infection and cervical cancers and warts associated therewith, made from compositions of this invention, are also disclosed. Nucleic acids and expression vectors coding for compositions of this invention are also disclosed.
Homogeneous Human Papillomavirus Capsomere Containing Compositions, Methods For Manufacture, And Use Thereof As Diagnostic, Prophylactic Or Therapeutic Agents
US Patent:
6165471, Dec 26, 2000
Filed:
Jul 2, 1998
Appl. No.:
9/109036
Inventors:
Robert L. Garcea - Boulder CO
JoAnn A. Suzich - Washington Grove MD
Michael P. McCarthy - Poolesville MD
Robert C. Rose - Dansville NY
JoAnn A. Suzich - Washington Grove MD
Michael P. McCarthy - Poolesville MD
Robert C. Rose - Dansville NY
Assignee:
University of Colorado, University Technology Corporation - Boulder CO
MedImmune, Inc. - Gaithersburg MD
University of Rochester, Office of Research and Project Administration
and Institute of Higher Education - Rochester NY
MedImmune, Inc. - Gaithersburg MD
University of Rochester, Office of Research and Project Administration
and Institute of Higher Education - Rochester NY
International Classification:
A61K 3912
US Classification:
4241861
Abstract:
The present invention relates to stable HPV capsomeres which express at least one virus-neutralizing conformational epitope of a native HPV L1 protein which are substantially incapable of assembly into virus-like particles. These capsomeres, because of their smaller size, and immunogenic properties are well suited for use in HPV vaccines and as diagnostic agents. Moreover, because of their smaller size (relative to VLPs), these stable capsomeres may be easily purified and should result in HPV vaccines of enhanced homogeneity.
Therapeutic And Prophylactic Vaccine For The Treatment And Prevention Of Papillomavirus Infection
US Patent:
2012008, Apr 12, 2012
Filed:
Sep 16, 2011
Appl. No.:
13/235218
Inventors:
Robert L. Garcea - Boulder CO, US
Renee Finnen - Kinston, CA
Renee Finnen - Kinston, CA
Assignee:
The Regents of the University of Colorado, a body corporate - Denver CO
International Classification:
A61K 39/12, A61P 37/04, C07H 21/04
US Classification:
4241861, 536 234
Abstract:
Embodiments of the present invention provide compositions including a complexes of papillomavirus capsid polypeptide L2 and polypeptide including an immunotherapeutic epitope, and GST fusions thereof. Other embodiments also provide complexes comprising chimeras of papillomavirus L2 polypeptides non-covalently associated with papillomavirus L1 polypeptides, and GST fusions thereof. These compositions may be used to elicit immune responses in a patient to papillomavirus. Therapeutic and prophylactic vaccines for the prevention and treatment of viral infection, especially papillomavirus infection and cervical cancers and warts associated therewith, made from compositions of this invention, are also disclosed. Nucleic acids and expression vectors coding for compositions are also disclosed.
Stable (Fixed) Forms Of Viral Capsid Proteins, And Viral Capsid Protein Fusions, Preferably Papillomavirus L1 Proteins, And Uses Thereof
US Patent:
7279306, Oct 9, 2007
Filed:
Jun 11, 2001
Appl. No.:
10/332037
Inventors:
C Richard Schlegel - Rockville MD, US
Robert Garcea - Boulder CO, US
Robert Garcea - Boulder CO, US
Assignee:
Georgetown University - Washington DC
University of Colorado - Aurora CO
University of Colorado - Aurora CO
International Classification:
C12P 21/06
US Classification:
435 691, 435 6
Abstract:
Novel acetone- or alcohol-fixed viral capsid proteins, bacteria-containing, and papillomavirus L1-GST fusion proteins are described. These proteins are useful in vaccine preparation and as diagnostics.
Dry Powder Formulations, Vaccines And Methods
US Patent:
2012004, Feb 23, 2012
Filed:
Oct 15, 2009
Appl. No.:
13/124701
Inventors:
Robert E. Sievers - Boulder CO, US
Robert L. Garcea - Boulder CO, US
Stephen P. Cape - Boulder CO, US
Robert L. Garcea - Boulder CO, US
Stephen P. Cape - Boulder CO, US
International Classification:
A61K 39/12, A61K 47/18, A61P 31/20, A61K 9/14
US Classification:
424400, 4242041, 4241921, 4242781
Abstract:
Respirable dry powder formulations comprise myo-inositol and leucine. Dry powder human papillomavirus (HPV) vaccine formulations comprise a least one HPV capsid protein and a carrier comprising myo-inositol and leucine. Methods of administering an HPV vaccine to an individual comprise inhalation administration to the individual of a dry powder HPV vaccine formulation comprising a least one HPV capsid protein and a carrier comprising myo-inositol and leucine.
Improved Methods For Protein Production
US Patent:
2011003, Feb 10, 2011
Filed:
Aug 27, 2008
Appl. No.:
12/669997
Inventors:
Robert L. Garcea - Boulder CO, US
Anton Middelberg - Brookfield, AU
Yap Pang Chuan - St. Lucia, AU
Anton Middelberg - Brookfield, AU
Yap Pang Chuan - St. Lucia, AU
International Classification:
C12P 21/00
US Classification:
435 697, 435 691
Abstract:
Methods for low cell-density bacterial protein expression that can achieve levels of up to 180 mg/l using a simple and low cost strategy. Full codon optimization is unnecessary to improve expression of viral genes rich in rare codons. Using a strategically modified host cell provides a simpler and cheaper alternative.